Abstract Oncotype DX Breast Recurrence Score® is a 21-gene prognostic and predictive
assay indicated for use in patients with hormone receptor-positive, human epidermal growth …

Purpose Prior studies examining cost effectiveness of the 21-gene assay (Oncotype DX
[ODX]) for women with hormone receptor–positive, early-stage breast cancer have yielded …

Abstract The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel
reviewed and endorsed substantial new evidence on aspects of the local and regional …

Gene expression profiles with prognostic capacities have shown good performance in
multiple clinical trials. However, with multiple assays available and numerous types of …

The Oncotype DX® assay was developed to address the need for optimizing the selection of
adjuvant systemic therapy for patients with estrogen receptor (ER)-positive, lymph node …

Purpose To evaluate the 21-gene recurrence score (RS) on decision-making in a population-
based cohort. Patients and Methods Patients with axillary node-negative or nodal …

BACKGROUND Breast cancer and its treatment can have an impact on health-related
quality of life and survival. Tumour profiling tests aim to identify whether or not women need …

Importance In 2006, the Centers for Medicare & Medicaid Services approved coverage for
the use of the 21-gene recurrence score (RS) assay in women with early-stage, estrogen …

Importance Guidelines recommend consideration of chemotherapy for most patients with
early-stage, estrogen receptor–positive, invasive breast cancer in the absence of additional …

Abstract Background. The 21-gene Onco type DX Recurrence Score assay is a validated
assay to help decide the appropriate treatment for estrogen receptor-positive (ER+), early …